Two Sigma Advisers
RPRX icon

Two Sigma Advisers’s Royalty Pharma RPRX Stock Holding History

Two Sigma Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-420,000
Closed -$16.2M – 1724
2025
Q4 		$16.2M Sell
420,000
-237,200
-36% -$9.05M 0.03% 401
2025
Q3 		$23.2M Sell
657,200
-189,700
-22% -$6.87M 0.05% 292
2025
Q2 		$30.5M Sell
846,900
-2,057,000
-71% -$68.2M 0.06% 259
2025
Q1 		$90.4M Sell
2,903,900
-769,300
-21% -$24.4M 0.2% 103
2024
Q4 		$93.7M Buy
3,673,200
+640,000
+21% +$17M 0.22% 86
2024
Q3 		$85.8M Buy
3,033,200
+936,900
+45% +$26M 0.2% 101
2024
Q2 		$55.3M Buy
2,096,300
+573,900
+38% +$15.9M 0.12% 156
2024
Q1 		$46.2M Sell
1,522,400
-478,700
-24% -$14.1M 0.11% 192
2023
Q4 		$56.2M Buy
2,001,100
+1,800
+0.1% +$49.5K 0.13% 167
2023
Q3 		$54.3M Buy
1,999,300
+1,051,700
+111% +$31.2M 0.14% 150
2023
Q2 		$29.1M Buy
947,600
+631,000
+199% +$21.4M 0.07% 240
2023
Q1 		$11.4M Sell
316,600
-271,100
-46% -$10.1M 0.03% 512
2022
Q4 		$23.2M Sell
587,700
-121,100
-17% -$5.05M 0.06% 298
2022
Q3 		$28.5M Sell
708,800
-43,200
-6% -$1.85M 0.08% 243
2022
Q2 		$31.6M Buy
752,000
+344,600
+85% +$14.1M 0.09% 237
2022
Q1 		$15.9M Buy
407,400
+133,400
+49% +$5.24M 0.04% 378
2021
Q4 		$10.9M Buy
274,000
+176,800
+182% +$6.87M 0.03% 483
2021
Q3 		$3.51M Buy
+97,200
New +$3.78M 0.01% 956

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Advisers's RPRX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 420,000 shares — an estimated $16.2M sold.

Two Sigma Advisers first reported a position in RPRX in Q3 2021 and held it in 18 quarters. The position peaked at $93.7M in Q4 2024. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 420,000 Royalty Pharma shares in Q1 2026, an estimated $16.2M.
  • Two Sigma Advisers first reported a position in Royalty Pharma in Q3 2021 and held it in 18 quarters.
  • Two Sigma Advisers's Royalty Pharma position peaked at $93.7M in Q4 2024.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.